Table 8.
Integrated CANVAS 1 and 2: clinical cure rates by infection type, underlying comorbidity and bacteremia status (CE population) at the test-of-cure visit
| Clinical diagnosis | Clinical cure rate (%)
|
||
|---|---|---|---|
| Ceftaroline | Vancomycin plus aztreonam | Difference, (%) (95% CI) | |
| Cellulitis | 93.0 | 91.4 | 1.7 (−3.4 to 6.7) |
| Major abscess | 91.1 | 94.1 | −3.0 (−8.5 to 2.3) |
| Infected wound | 86.9 | 89.0 | −2.2 (−12.8 to 8.7) |
| Infected ulcer | 90.6 | 94.0 | −3.5 (−15.7 to 8.3) |
| Infected burn | 100 | 100 | 0.0 (−13.6 to 17.9) |
| Infected bite | 100 | 100 | 0.0 |
| Other | 80.0 | 100 | −20.0 |
| Underlying comorbidity | |||
| Diabetes mellitus | 87.3 | 90.9 | −3.5 (−12.2 to 5.0) |
| Peripheral vascular disease | 88.9 | 89.3 | −0.2 (−10.0 to 9.7) |
| Bacteremia | 84.6 | 100 | −15.4 (−33.8 to 1.5) |
| Staphylococcus aureus | 88.9 | 100 | −11.1 (−33.2 to 5.7) |
| MRSA | 85.7 | 100 | −14.3 (−53.5 to 58.4) |
Note: Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: Phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51(6):641–650, by permission of Oxford University Press.66
Abbreviations: CANVAS, ceftaroline versus v ancomycin in skin and skin structure infections; CE, clinically evaluable; CI, confidence interval; MRSA, methicillin-resistant Staphylococcus aureus.